REIG JOFRE, a leading Spanish pharmaceutical company listed on the Spanish stock exchange (BME: RJF), has strengthened its presence in Central and Eastern Europe (CEE) with the launch of a new subsidiary in the Czech Republic. Building on its international growth strategy, the new RJ Czech Republic branch focuses on osteoarticular health and dermatology, key segments for the company’s Specialty Pharmacare unit.

With operations commencing in the second half of 2024, REIG JOFRE aims to expand its reach in the Czech pharmaceutical market, where the musculoskeletal and dermatology segments saw rapid growth, with €175 million and €77 million in sales, respectively, in 2023. By introducing its innovative healthcare solutions, REIG JOFRE plans to capture further market share and enhance patient outcomes in these critical areas.

The company will collaborate with local partner LERAM Pharma to strengthen its distribution network and streamline access to its osteoarticular and dermatology products. The establishment of RJ Czech Republic reflects REIG JOFRE's commitment to forging partnerships and leveraging local expertise to drive growth in the CEE region.

In a future phase, REIG JOFRE will expand its product offering in the Czech Republic to include items from its Consumer Healthcare unit, covering categories such as weight control, energy, stress and sleep management, and beauty products. Additionally, the company plans to introduce hospital injectables from its Pharmaceutical Technologies unit, once regulatory approvals are secured.

REIG JOFRE’s international expansion has been a cornerstone of its growth, with the company now operating subsidiaries in several strategic European markets, including Spain, France, Belgium, Sweden, and Poland. The opening of its Czech subsidiary follows the successful launch of its Polish office in 2021, further consolidating the company’s distribution network and market presence across Central Eastern Europe.

With 55% of its international revenue stemming from its own sales network across Europe, and distribution partnerships in over 70 countries, REIG JOFRE continues to advance its global strategy. The company closed 2023 with sales of €316 million, with the Specialty Pharmacare and Consumer Healthcare units contributing 33% and 23% of total revenue, respectively.

This expansion into the Czech Republic underlines REIG JOFRE's commitment to growing its presence in CEE, enhancing its partnership search efforts, and driving new opportunities with local distribution partners across the region.